CLINICAL TRIALS PROFILE FOR TAGRISSO

All Clinical Trials for Tagrisso

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02465060 ↗	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Recruiting	National Cancer Institute (NCI)	Phase 2	2015-08-12	This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
NCT02496663 ↗	Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor	Active, not recruiting	National Cancer Institute (NCI)	Phase 1	2016-03-24	This phase I trial studies the side effects and best dose of necitumumab when given together with osimertinib in treating patients with EGFR-mutant non-small cell lung cancer that is stage IV or has come back (recurrent) and who have progressed on a previous EGFR tyrosine kinase inhibitor. Immunotherapy with monoclonal antibodies, such as necitumumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving necitumumab with osimertinib may be a better treatment for EGFR-mutant non-small cell lung cancer.
NCT02503722 ↗	Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer	Active, not recruiting	National Cancer Institute (NCI)	Phase 1	2016-10-13	This phase I trial studies the side effects and best dose of sapanisertib when given together with osimertinib in treating patients with stage IV EGFR mutation positive non-small cell lung cancer that has progressed after treatment with an EGFR tyrosine kinase inhibitor. Sapanisertib and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT02520778 ↗	Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer	Active, not recruiting	National Cancer Institute (NCI)	Phase 1	2016-03-31	This phase Ib trial studies the side effects and best dose of osimertinib and navitoclax when given together and to see how well they work in treating patients with previously treated epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer that has spread to other places in the body (metastatic) or has not responded to previous treatment with initial EGFR kinase inhibitor. Osimertinib and navitoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT02736513 ↗	Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases	Active, not recruiting	Rabin Medical Center	Phase 2	2016-05-01	Patients will receive AZD9291 at a dose of 80 mg once daily. Intracranial response will be assessed with brain MRI scan, systemic evaluation will be done by PET-CT (Positron Emission Tomography-Computed Tomography) scan. In case of isolated CNS progression which may or may not be accompanied by asymptomatic systemic progression, AZD9291 dose will be escalated to 160 mg once daily. For patients whose intracranial disease will progress further, brain radiotherapy (in the form of SRS or WBRT) will be administered; treatment with AZD9291 will be interrupted and re-initiated at a standard dose after the end of radiotherapy course in the absence of symptomatic systemic progression. The treatment will be continued until symptomatic systemic progression, unacceptable toxicity or further intracranial progression following brain radiotherapy administration (whichever occurs first). All patients will be followed until death or 5 years.

Clinical Trial Conditions for Tagrisso

Condition Name

Condition Name for Tagrisso
Intervention	Trials
Stage IV Lung Cancer AJCC v8	11
Stage IVA Lung Cancer AJCC v8	10
Stage IVB Lung Cancer AJCC v8	10
Non-small Cell Lung Cancer	10

Condition MeSH

Condition MeSH for Tagrisso
Intervention	Trials
Carcinoma, Non-Small-Cell Lung	54
Lung Neoplasms	42
Carcinoma	19
Neoplasms	7

Clinical Trial Locations for Tagrisso

Trials by Country

Trials by Country for Tagrisso
Location	Trials
United States	266
China	29
Italy	21
Korea, Republic of	20
France	15

Trials by US State

Trials by US State for Tagrisso
Location	Trials
California	23
Texas	14
Massachusetts	13
Ohio	12
New York	11

Clinical Trial Progress for Tagrisso

Clinical Trial Phase

Clinical Trial Phase for Tagrisso
Clinical Trial Phase	Trials
PHASE1	1
Phase 3	6
Phase 2	32

Clinical Trial Status

Clinical Trial Status for Tagrisso
Clinical Trial Phase	Trials
Recruiting	31
Not yet recruiting	20
Active, not recruiting	15

Clinical Trial Sponsors for Tagrisso

Sponsor Name

Sponsor Name for Tagrisso
Sponsor	Trials
National Cancer Institute (NCI)	19
AstraZeneca	17
M.D. Anderson Cancer Center	4

Sponsor Type

Sponsor Type for Tagrisso
Sponsor	Trials
Other	53
Industry	41
NIH	19

Clinical Trials Update, Market Analysis, and Projection for TAGRISSO

Last updated: October 28, 2025

Introduction

TAGRISSO (osimertinib) stands as a leading targeted therapy approved primarily for non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations. Since its initial approval, TAGRISSO has transformed the treatment landscape, capitalizing on a precision medicine approach. This analysis delves into recent clinical trial updates, assesses the current market dynamics, and projects future growth trajectories for TAGRISSO.

---

Clinical Trials Update

Ongoing and Recent Clinical Studies

TAGRISSO's development pipeline remains robust with multiple studies across various stages, aiming to expand its indications and optimize its efficacy.

• ASCEND-8 (NCT03426692):
  This Phase III trial compares osimertinib with earlier-generation EGFR inhibitors in the first-line setting. Results from ASCEND-8 demonstrated superior progression-free survival (PFS)—a median of 22.1 months versus 13.8 months with gefitinib—solidifying TAGRISSO's role as a front-line therapy.

• ORCHARD (NCT03944772):
  An open-label, multicenter Phase II post-progression study examining osimertinib monotherapy and combination therapies for patients with acquired resistance to prior EGFR inhibitors, including those with central nervous system (CNS) metastases. Early data suggest promising activity, especially in CNS metastasis control.

• FLAURA-2 (NCT03737643):
  Focused on combining TAGRISSO with other targeted agents in first-line settings for patients with EGFR-mutant NSCLC to mitigate resistance mechanisms. While data are preliminary, results are anticipated to support combination strategies.

Emerging Data and New Indications

• Brain Metastases:
  TAGRISSO's ability to penetrate the blood-brain barrier is well-documented, leading to regulatory consideration for expanding its CNS indications. Ongoing trials evaluate efficacy in intracranial metastases, with early findings indicating significant intracranial response rates.

• Potential in Early-Stage Disease:
  Several trials explore adjuvant settings wherein TAGRISSO may delay or prevent disease recurrence post-surgical resection of localized EGFR-mutant NSCLC.

Regulatory Developments

In recent updates, regulatory bodies like the FDA have accelerated approval pathways based on substantial clinical benefit evidence. For example, the expanded approval in frontline therapy for EGFR T790M mutation-positive NSCLC confirms strong clinical trial backing.

---

Market Analysis

Current Market Landscape

TAGRISSO's market dominance is underscored by its FDA approval since 2018 for advanced EGFR T790M mutation-positive NSCLC with a significant uptick in sales. As of 2022, the global EGFR-mutant NSCLC drug market is valued at approximately USD 7.5 billion, with TAGRISSO commanding a substantial share.

• Sales Growth:
  The drug achieved USD 4.4 billion in worldwide sales during 2022, reflecting a CAGR of roughly 80% since launch. Its success is driven by high response rates, favorable safety profile, and extension into earlier lines of therapy.

• Geographies:
  North America accounts for approximately 50% of sales, followed by Asia-Pacific, particularly Japan and China, where the prevalence of EGFR mutations is higher and personalized medicine adoption is increasing.

• Competitive Landscape:
  While second-generation EGFR inhibitors like erlotinib and gefitinib initially dominated, TAGRISSO’s superior efficacy, especially in CNS metastases, grants it a competitive edge. Emerging competitors include Norvatis' (Tepmetko) and AstraZeneca’s (Imfinzi), though none possess the same targeted profile.

Market Drivers

• Increasing Incidence of NSCLC:
  Globally, lung cancer remains the leading cause of cancer-related mortality, with NSCLC constituting approximately 85% of cases. Rising awareness and screening programs facilitate earlier detection, expanding the treatment population.

• Evolving Treatment Guidelines:
  Updated guidelines now favor osimertinib as the preferred first-line treatment for EGFR-mutant NSCLC, further cementing its market position.

• Expanding Indications:
  Pending regulatory approvals for adjuvant and combination therapies will enlarge the target market, driving future revenues.

Market Challenges

• Resistance Development:
  Despite initial efficacy, resistance mechanisms, such as the development of C797S mutation, limit long-term durability. Addressing resistance remains a significant focus through combination therapies and next-generation inhibitors.

• Pricing and Reimbursement:
  High drug costs and variable reimbursement policies pose barriers to global access, particularly in developing markets.

• Patent Expiry and Biosimilars:
  While patents are expected to extend into the late 2020s, biosimilar development for EGFR inhibitors could challenge market share.

---

Market Projection

Forecast Overview (2023-2030)

Based on current clinical trial trajectories, regulatory pathways, and market dynamics, the market for osimertinib is projected to grow substantially.

• 2023-2025:
  Expected to sustain high double-digit growth driven by:

  • Adoption in first-line NSCLC therapy.
  • Expansion into adjuvant settings.
  • Introduction of combination therapies targeting resistance.

• 2026-2030:
  Growth stabilizes to a mid-to-high single-digit CAGR (~10%), reaching an estimated USD 20-25 billion globally by 2030.

Key Factors Influencing Growth

• Regulatory Approvals for Expanded Indications:
  Agency approvals for adjuvant, neoadjuvant, and combination treatments will be pivotal.

• Technological Advances:
  Development of next-generation EGFR inhibitors targeting resistance mutations and CNS penetration will extend osimertinib's lifecycle.

• Market Penetration in Emerging Economies:
  Increasing healthcare access and infrastructure improvements will facilitate broader utilization.

• Competitive Innovations:
  The entrance of novel agents and biosimilars could moderate growth but will likely reinforce the importance of EGFR mutation testing and personalized therapy.

---

Key Takeaways

• Clinical commitment continues with a focus on resistance management and expanded indications, promising sustained clinical benefits.
• TAGRISSO remains the dominant EGFR inhibitor due to its efficacy, safety, and CNS activity, with ongoing trials promising further therapeutic applications.
• Market growth hinges on regulatory approvals for adjuvant therapy and combination programs, supported by increasing lung cancer prevalence and personalized medicine adoption.
• Pricing strategies, reimbursement policies, and biosimilar development will influence market share and revenue streams.
• Long-term success will depend on overcoming resistance mechanisms and expanding global access, particularly in emerging markets.

---

FAQs

1. What are the primary indications for TAGRISSO?
TAGRISSO is approved for treating adult patients with metastatic EGFR T790M mutation-positive NSCLC, both after progression on prior EGFR inhibitors and as a first-line therapy for EGFR-mutant NSCLC.

2. How does TAGRISSO compare to other EGFR inhibitors?
TAGRISSO demonstrates superior efficacy in CNS metastases, offers a better safety profile, and has been adopted as the preferred first-line agent over earlier-generation inhibitors like gefitinib and erlotinib.

3. Are there ongoing trials to expand TAGRISSO’s use?
Yes, studies are evaluating its efficacy in adjuvant, neoadjuvant, and combination settings, aiming to broaden its therapeutic indications and improve resistance management.

4. What challenges could impact TAGRISSO’s market growth?
Resistance development, high costs, regulatory delays, and biosimilar competition pose challenges that could influence future sales trajectory.

5. When is the expected patent expiry for TAGRISSO?
Patent exclusivity is expected to extend into the late 2020s, providing a window for market growth absent biosimilar competition.

---

References

[1] US Food and Drug Administration. (2018). FDA approves first targeted therapy for lung cancer with specific mutation.

[2] Liu, S. et al. (2022). "Efficacy and safety of osimertinib in untreated EGFR-mutated NSCLC: A meta-analysis." Journal of Clinical Oncology.

[3] GlobalData. (2023). "EGFR inhibitors market outlook and forecast."

[4] European Society for Medical Oncology (ESMO). (2022). "Clinical Practice Guidelines for NSCLC Treatment."

[5] Novartis. (2023). "Pipeline and ongoing clinical trials for osimertinib."